Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Finerenone in Pediatric Henoch-Schönlein Purpura Nephritis With Mild Proteinuria
NCT07315191Phase 4Recruiting
- Sponsor
- Capital Institute of Pediatrics
- Start
- Jun 2025
- Primary completion
- Oct 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of finerenone in IgA vasculitis nephritis (2 arms), sponsored by Capital Institute of Pediatrics. Primary endpoint: Percentage of Subjects with a Reduction in 24-Hour Urinary Protein Excretion ≥30% from Baseline at 3 months. Started Jun 2025; status: recruiting.
02
Drugs
finerenone
03
Conditions
IgA vasculitis nephritis
Beyond the preview
Go deeper on NCT07315191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07315191.